AAIC 2024 at a Glance
This year, more than 14,000 members of our scientific community gathered in Philadelphia and online. AAIC 2024 brought together dementia researchers from all areas of practice and career stages to exchange ideas and build connections. Together, we’re elevating careers and advancing the future of dementia science.
2024 Press Releases
- Alzheimer’s Disease Blood Tests Could Improve Diagnosis, Support Recruiting for Research and Speed Access to Treatment
- Exposure to Wildfire Smoke Greatly Raises Risk of Dementia Diagnosis
- GLP-1 Drug Liraglutide May Protect Against Dementia
- Processed Red Meat Raises the Risk of Dementia; Swapping It For Nuts and Beans May Lower Risk
2024 News Highlights
Plenary Sessions
Maria C. Carrillo, Ph.D., chief science officer and medical affairs lead of the Alzheimer’s Association, welcomes more than 14,000 in-person and virtual attendees to AAIC 2024.
Philadelphia’s own Edward B. Lee, M.D., Ph.D., presents his plenary session, "Neuropathology in a Multidisciplinary Age."
Timothy Miller, M.D., Ph.D. , presents his plenary session, "Antisense Oligonucleotide Therapeutics for Neurodegenerative Diseases."
Henne Holstege, Ph.D., presents her plenary session, "From Longevity to Vulnerability: Genomic Pathways Underlying Cognitive Health in Centenarians and Neurodegenerative Disease."
Suvarna Alladi, DM, presents her plenary session, "Bilingualism and Dementia: Implications for Brain Health and Policy Development."
Clive Ballard, M.D., Ph.D., presents his plenary session, "Psychosis in Alzheimer's Disease."
Tara Spires-Jones, Ph.D., winner of the Inge Grundke-Iqbal Award for Alzheimer's Research, presents her plenary session, "Synaptic Oligomeric Tau in Alzheimer’s Disease — A Potential Culprit in the Spread of Tau Pathology Through the Brain."
Ricardo F. Allegri, M.D., Ph.D., presents his plenary session, "Dementia Research in Low- and Middle- Income Countries (LMICs): Initiatives That Seize Opportunities, Overcome Challenges and Build Capacity."
Reisa Sperling, M.D., presents her plenary session, "Preclinical AD."
Michael Weiner, M.D., presents his plenary session, "ADNI: Two Decades of Impact and the Path Forward."
